
Aeglea BioTherapeutics (AGLE) Stock Forecast & Price Target
Aeglea BioTherapeutics (AGLE) Analyst Ratings
Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%
Aeglea BioTherapeutics (AGLE) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Aeglea BioTherapeutics and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Aeglea BioTherapeutics and is not a guaranteed prediction by Public.com or investment advice.
Aeglea BioTherapeutics (AGLE) Analyst Forecast & Price Prediction
Get the latest Aeglea BioTherapeutics (AGLE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Aeglea BioTherapeutics (AGLE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Aeglea BioTherapeutics (AGLE) Forecast
Analysts have given Aeglea BioTherapeutics (AGLE) a Buy based on their latest research and market trends.
According to 8 analysts, Aeglea BioTherapeutics (AGLE) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $10.92, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $10.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.